BioSpace News Archive

Patients are being followed for up to 2 years, and the median follow-up at the time of the analysis is approximately 18 months.

The gross proceeds to Arsanis from the offering are expected to be $40.0 million, before deducting underwriting discounts and commissions and other offering expenses.

Egalet-002 was generally well-tolerated and the incidence of adverse events reported was generally consistent with outcomes expected following treatment with an extended-release oxycodone formulation.

The conference is being held November 16-19, 2017 in San Francisco, CA.

Summit is a drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection.

Revenues of €44.7 million (2016: €68.9 million).

Orphazyme has today implemented a new long-term incentive programme.

Wize today announced the closing of its previously announced merger with Wize Pharma Ltd., a clinical-stage biopharmaceutical company, focused on the treatment of ophthalmic disorders. In connection with the merger, Wize Israel’s ordinary shares were delisted from the Tel Aviv Stock Exchange and from November 16, 2017, Wize’s common stock will be quoted on the OTC Pink under the symbol “WIZP”.

The TOBA study enrolled 138 subjects at 13 sites in Europe.

Mr. DiIorio has served as a member of the Company’s Office of the President since May 2017.